CAPZA1: A Potential Drug Target and Biomarker (G829)

Target Name: CAPZA1

NCBI ID: G829

CAPZA1

CAPZA1: A Potential Drug Target and Biomarker

CAPZA1, or Cap Z, is a protein that is expressed in various tissues of the brain, including the cerebral cortical cortical and cerebellar regions. It is a member of the Z-wheel family of transmembrane proteins, which are involved in the regulation of ion channels and neurotransmitter release.

The CAPZA1 gene was first identified in 2008, and its function has been extensively studied in the context of neurological and psychiatric disorders. Initial studies suggested that CAPZA1 may be involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. This is thought to be important for the development and progression of conditions such as Alzheimer's disease, Parkinson's disease, and other forms of neurodegeneration.

In addition to its potential role in neuroplasticity, CAPZA1 has also been shown to be involved in the regulation of pain perception and neuroinflammation. This is important because pain perception and neuroinflammation are often associated with neurodegenerative disorders, and may contribute to the development and progression of these conditions.

Given the potential involvement of CAPZA1 in neuroplasticity and pain perception, it is a promising target for drug development. Studies have shown that blocking CAPZA1 with small molecules has the potential to alleviate symptoms of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

In addition to its potential therapeutic applications, CAPZA1 is also a potential biomarker for the diagnosis and monitoring of neurodegenerative disorders. The loss of CAPZA1 has been observed in the brains of individuals with Alzheimer's disease, and this is thought to be a potential diagnostic biomarker. Similarly, the levels of CAPZA1 have been shown to be elevated in the brains of individuals with Parkinson's disease, and this may be a potential diagnostic biomarker for this condition as well.

Given the potential involvement of CAPZA1 in neuroplasticity, pain perception, and neuroinflammation, as well as its potential as a biomarker for neurodegenerative disorders, CAPZA1 is a promising target for further research and development. Further studies are needed to fully understand the function of CAPZA1 and its potential as a drug target and biomarker.

Protein Name: Capping Actin Protein Of Muscle Z-line Subunit Alpha 1

Functions: F-actin-capping proteins bind in a Ca(2+)-independent manner to the fast growing ends of actin filaments (barbed end) thereby blocking the exchange of subunits at these ends. Unlike other capping proteins (such as gelsolin and severin), these proteins do not sever actin filaments. May play a role in the formation of epithelial cell junctions (PubMed:22891260). Forms, with CAPZB, the barbed end of the fast growing ends of actin filaments in the dynactin complex and stabilizes dynactin structure. The dynactin multiprotein complex activates the molecular motor dynein for ultra-processive transport along microtubules (By similarity)

The "CAPZA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CAPZA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets